<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02092207</url>
  </required_header>
  <id_info>
    <org_study_id>KL7016_201</org_study_id>
    <nct_id>NCT02092207</nct_id>
  </id_info>
  <brief_title>Phase 2 Study to Evaluation the Safety and Efficacy of Orally Administered KL7016 in Patients With Dry Eye Syndrome</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, 12 Weeks, Phase II Clinical Study to Evaluate the Safety and Efficacy of Orally Administered KL7016 in Patients With Dry Eye Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yungjin Pharm. Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yungjin Pharm. Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a controlled study to determine the effectiveness and safety of KL7016 in the
      treatment of adult patients with dry eye syndrome (DES).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in corneal staining score</measure>
    <time_frame>baseline, 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in schirmer test score</measure>
    <time_frame>baseline, 4weeks, 8weeks, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in OSDI(Ocular Surface Disease Index)</measure>
    <time_frame>baseline, 4weeks, 8weeks, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in TFBUT(Tear Film Break-up Time)</measure>
    <time_frame>baseline, 4weeks, 8weeks, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in conjunctival staining score</measure>
    <time_frame>baseline, 4weeks, 8weeks, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in corneal staining score</measure>
    <time_frame>baseline, 4weeks, 8weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">147</enrollment>
  <condition>Dry Eye Syndrome</condition>
  <arm_group>
    <arm_group_label>KL7016 900mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>KL7016 600mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KL7016 900mg</intervention_name>
    <description>oral administration, 150mg 3tab, bid</description>
    <arm_group_label>KL7016 900mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KL7016 600mg</intervention_name>
    <description>oral administration, 150mg 3tab, bid</description>
    <arm_group_label>KL7016 600mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral administration, 150mg 3tab, bid</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Corneal staining score of ≥5 in either eye by the National Eye Institute/Industry
             Workshop guidelines

          -  Schirmer test score (without anesthesia) &lt; 7 mm/5 min in either eye

          -  Willing to use no topical ocular treatments, other than REFRESH TEARS® for the
             duration of the trial

        Exclusion Criteria:

          -  Intraocular surgery within 3months

          -  Persistent intraocular inflammation or infection

          -  Corneal transplantation or neurotrophic keratitis

          -  Stevens-Johnson Syndrome

          -  Ocular herpes simplex virus infection

          -  Concomitant use of contact lenses or use within 3months

          -  Silicone lacrimal punctal occlusion or cauterization of the punctum within 3months

          -  Vision correction surgery without DES within 12months

          -  Unstable use of methotrexate or Disease-modifying drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Catholic University of Korea, Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Banpo-daero, Seocho-gu</state>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Eonju-ro, Gangnam-gu</state>
        <zip>135-720</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Gyeonggi-do</city>
        <state>Gumi-ro 173 Beon-gil Bundang-gu</state>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Gurodong-ro, Guro-gu</state>
        <zip>152-703</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Irwon-ro, Gangnam-gu</state>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hospital</name>
      <address>
        <city>Gwangju</city>
        <state>Jebong-ro, Dong-gu</state>
        <zip>501-757</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Konkuk University Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Neungdong-ro, Gwangjin-gu</state>
        <zip>143-729</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASAN Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Olympic-ro 43-gil, Songpa-gu</state>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Yonsei-ro, Seodaemun-gu</state>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 17, 2014</study_first_submitted>
  <study_first_submitted_qc>March 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2014</study_first_posted>
  <last_update_submitted>December 19, 2017</last_update_submitted>
  <last_update_submitted_qc>December 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

